A Phase 1 interventional study of BH3120 and pembrolizumab in Advanced or Metastatic Solid Tumors, sponsored by Hanmi Pharmaceutical Company Limited. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation part is planned to establish the MTD or RD for Dose-Expansion part, while Dose-Expansion part is designed to assess potential efficacy of BH3120, as a single agent and in combination with pembrolizumab, when administered at the RD to subjects in indication-specific expansion cohorts.
Key Inclusion Criteria:
Key Exclusion Criteria:
Arm A: BH3120 Monotherapy
Drug: BH3120
Arm B: BH3120 in combination with pembrolizumab
Drug: BH3120 · Drug: pembrolizumab
BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle
Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle
Also known as: KEYTRUDA®
Incidence, nature, and severity of adverse events and laboratory abnormalities graded per NCI-CTCAE v5.0.
To evaluate safety and tolerability of BH3120 as a single agent and in combination with pembrolizumab administration
Time frame: Throughout the study until end of safety follow-up period (90 days after the last treatment)
Incidence and nature of DLTs
To evaluate safety and tolerability of BH3120 as a single agent and in combination with pembrolizumab administration
Time frame: At the end of Cycle 1 (each cycle is 21 days) in Dose-Escalation Part
The maximum serum concentration (Cmax)
To evaluate PK profile upon BH3120 administration
Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)
The time to reach Cmax (Tmax)
To evaluate PK profile upon BH3120 administration
Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)
The area under the concentration-time curve from time 0 to the last observable concentration (AUClast)
To evaluate PK profile upon BH3120 administration
Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)
The AUC during the dosing interval (AUCtau)
To evaluate PK profile upon BH3120 administration
Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)
The AUC extrapolated to infinity (AUCinf)
To evaluate PK profile upon BH3120 administration
Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)
The terminal half-life (T1/2)
To evaluate PK profile upon BH3120 administration
Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)
The apparent clearance (CL/F)
To evaluate PK profile upon BH3120 administration
Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)
The apparent volume of distribution (Vd/F)
To evaluate PK profile upon BH3120 administration
Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)
Frequency of anti-drug antibodies (ADA) and neutralizing antibodies (NAb)
Immunogenicity of BH3120
Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)
Objective response rate (ORR)
ORR will be measured as the proportion of subjects with a confirmed response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Time frame: Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)
Disease Control Rate (DCR)
DCR will be measured as the proportion of subject with confirmed CR, PR, or Stable Disease (SD) as per RECIST v1.1
Time frame: Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)
Duration of response (DOR)
DOR will be measured as the time from initial onset of CR or PR to first radiographic progression as per RECIST v. 1.1 or death from any cause, whichever occurs first.
Time frame: Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)
Progression-free survival (PFS)
PFS will be measured from date of first treatment until date of radiographic progression as per RECIST v.1.1 or until death from any cause, whichever occurs first
Time frame: Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanmi Pharmaceutical Company Limited